Literature DB >> 7446471

Heparin and the activated partial thromboplastin time--a difference between the in-vitro and in-vivo effects and implications for the therapeutic range.

B Bain, T Forster, B Sleigh.   

Abstract

The in-vivo sensitivity to heparin of activated partial thromboplastin time (aPTT) reagents is different from the in-vitro sensitivity. Equivalent therapeutic ranges for reagents of very different sensitivities may be determined from the regression line of aPTT against whole blood clotting time. The commonly used ratio of 1.5 to 2.5 times the normal control value is appropriate for some reagents, but for the other reagents a higher or lower range is appropriate. A suitable aPTT reagent for heparin control should be sensitive both to a threshold effect of heparin and to increasing dosage. Some reagents discriminate poorly at the threshold level.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7446471     DOI: 10.1093/ajcp/74.5.668

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  5 in total

Review 1.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage.

Authors:  S Kitchen; I Jennings; T A Woods; F E Preston
Journal:  J Clin Pathol       Date:  1996-01       Impact factor: 3.411

Review 3.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

4.  Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease.

Authors:  M Cullberg; U G Eriksson; M Larsson; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

5.  Establishing a new target range for unfractionated heparin for acute coronary syndromes.

Authors:  Michael S Lee; Venu Menon; Joseph Schappert; James R Wilentz; Varinder Singh; Judith S Hochman
Journal:  J Thromb Thrombolysis       Date:  2004-04       Impact factor: 2.300

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.